Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

0.6530 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
Company to highlight potential of its small molecule therapeutics that enhance the HGF/MET system to treat a variety of neurodegenerative diseases 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma, Inc. (NASDAQ:ATHA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/06/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Athira Pharma, Inc. 
Via SBWire
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Outlines Possible Comeback For Alzheimer's Candidate
Via Benzinga
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma: Q2 Earnings Insights
  Athira Pharma (NASDAQ:ATHA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
4 Analysts Have This to Say About Athira Pharma
Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter: 
Via Benzinga
NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc.
San Diego, CA -- (SBWIRE) -- 01/18/2023 -- The Shareholders Foundation announced an update in the lawsuit that was filed on behalf of certain investors in Athira Pharma, Inc. (NASDAQ:ATHA). 
Via SBWire
Athira Pharma Provides 2023 Pipeline Outlook
From Athira Pharma, Inc.
Via GlobeNewswire
4 Penny Stocks Insiders Are Buying: Athira Pharma, Great Elm Group And More
US stocks recorded losses for 2022. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's... 
Via Benzinga
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models 
From Athira Pharma, Inc.
Via GlobeNewswire
Beachbody, Athira Pharma And This Penny Stock Insiders Are Aggressively Buying
The Dow Jones closed lower by nearly 350 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration 
From Athira Pharma, Inc.
Via GlobeNewswire
Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Present at Stifel 2022 Healthcare Conference
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy 
From Athira Pharma, Inc.
Via GlobeNewswire
Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
From Athira Pharma, Inc.
Via GlobeNewswire
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More
Morgan Stanley cut Westinghouse Air Brake Technologies Corporation (NYSE: WAB) price target from $113 to $94. Westinghouse Air Brake Technologies shares fell 1.7% to $82.36 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.